Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 2

Conditions

Oligodendroglioma 1Healthy Adult Participants 1Glioma 1Astrocytoma 1

Interventions

pembrolizumab 604Carboplatin 374Paclitaxel 283Cisplatin 270Gemcitabine 252Pemetrexed 194Bevacizumab 191Docetaxel 186Nivolumab 180Injections 169Cyclophosphamide 150atezolizumab 139Fluorouracil 134Capecitabine 133Oxaliplatin 132Dexamethasone 128durvalumab 113Fulvestrant 113130-nm albumin-bound paclitaxel 110fludarabine 103Cetuximab 100Leucovorin 97Rituximab 95venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 77Azacitidine 74Irinotecan 73Doxorubicin 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × vorasidenib × 1 year × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Servier

Phase 1 Completed
28 enrolled

Healthy Adult Participants

NCT07240662 2026-01-09

VIOLETA

iOMEDICO AG

Recruiting
150 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡